Navigation Links
Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned

Additional beneficial effects on cardiometabolic risk factors beyond those expected from weight loss in trials of the anti-obesity drug rimonabant may not be due to the drug itself, reports an article in the June issue of Drug and Therapeutics Bulletin (DTB).

Advertisements for rimonabant (sold under the brand name Acomplia by Sanofi-Aventis) claim that an estimated 50% of the effects on cardiometabolic risk factors are beyond those expected from weight loss alone. But DTB argues that these effects are not proven to be due to the drug itself.

Also, no published trials have compared rimonabant with either of the other anti-obesity drugs orlistat or sibutramine. Instead, rimonobants effects on weight have been assessed in four double-blind trials comparing the drug with placebo.

The article says: In three of the trial reports, the authors state that the effects of rimonabant on HDL, triglycerides and HBA1c were partly independent of weight loss. However, it is not proven that any independent effect is wholly or partially attributable to rimonabant.

The article suggests that these observed effects might be related to increased activity based on the lifestyle advice given to participants at the start of the trials.

Furthermore, it is not known whether rimonabants effects on individual risk factors translate into a reduced long-term likelihood of cardiovascular events, the article adds.

. Rimonabant has not been directly compared with other, less expensive, drug treatments for obesity. Orlistat is the drug for obesity for which there is the most evidence for efficacy and safety to date, and we have previously concluded that it is a reasonable option for obese patients where diet and exercise and/or behavioural measures alone have failed.

Rimonabant is the most expensive of the anti-obesity drugs. A years treatment with rimonabant 20mg daily costs the NHS around 720, compar ed with 520 for orlistat 120 mg three times daily and 480-570 for sibutramine 10-15 mg daily.


'"/>




Related medicine news :

1. Anti-obesity drugs for FDA approval
2. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
3. Lean Protein Could Be Key to Obesity Drugs
4. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
5. Nasal Spray Could Take Drugs Direct to Brain.
6. Emphasis to ban Drugs ads by Doctors
7. Osteoporosis Drugs: right time to take-off
8. Drugs disrupt formation of blood vessels
9. Drugs to stop burgeon of HIV
10. Misleading Advertisements for Prescription Drugs
11. Drugs For Anthrax May Interfere With Oral Contraceptives
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... ... 10 Best Water is excited to announce a new monthly ... topped the list as a result of their commitment to offering clients creative, customized, ... 5100, a top notch water company that specializes in providing the public with refreshing ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), ... latest addition to its growing list of Partner Firms. S.S. Nesbitt is ... Orlando to Huntsville and in between. , Harnessing the experience and insights of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... change in their patients. Research shows that the Goal Attainment Scale (GAS) captures ... overcome this challenge and learn more about the Goal Attainment Scale, Education Resources ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the ... a solution that ensures the integrity of biological samples while operating at ultra-high ...
(Date:2/10/2016)... DC (PRWEB) , ... February 10, 2016 , ... Anxiety ... level since the start of Medicare Part D a decade ago, according to ... comments from older adults on how they are coping with rapidly rising costs. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Visage Imaging Inc. ("Visage"), a wholly owned ... that the American College of Radiology (ACR) and ... Visage 7 Enterprise Imaging Platform as the new ... SIMulation (SIM). SIM is the assessment component of ... multi-faceted and fully-integrated online assessment, education and remediation ...
(Date:2/10/2016)... Mast Therapeutics, Inc. (NYSE MKT: ... sickle cell disease and heart failure, today announced the ... at a price to the public of $0.275 per ... Company,s common stock and one warrant to purchase one ... price of $0.42 per share. The warrants are exercisable ...
(Date:2/10/2016)... New York , February 10, 2016 ... Growth, Trends and Forecast 2015 - 2023 ", reveals that ... rather slow growth from 2015 to 2023 owing to patent ... a meager CAGR of 1.30% during the forecast period, the ... to US$38.9 bn in 2023. --> Antibacterial Drugs ...
Breaking Medicine Technology: